Work

Phase II study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma (rGBM).

Year: 2010

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2010.28.15_suppl.2011

Authors: D. Schiff, D. A. Reardon, S. Kesari, T. Mikkelsen, J. F. De Groot, L. Fichtel, T. E. Coyle, E. Wong, C. Eaton, B. Silver

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2247406157

Cites:

Cited by: 15

Related to: 10